Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEN-K vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Treatment and prevention of hypokalemia,Hypokalemia associated with diuretic therapy,Hypokalemia in patients with digitalis toxicity
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
10 m Eq (one tablet) orally once daily or as directed by physician.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Terminal elimination half-life is approximately 30-60 minutes; clinical context: short half-life necessitates frequent dosing for maintenance of potassium levels.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium chloride is not metabolized; it is absorbed and excreted primarily by the kidneys. Approximately 90% is eliminated in urine, with the remainder in feces and sweat.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Renal: >90% excreted unchanged by the kidneys; fecal: <5%
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Minimal (<10%); not significantly bound to plasma proteins.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
Approximately 0.2-0.4 L/kg; reflects distribution primarily in extracellular fluid.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Oral: 100% (potassium chloride is well absorbed); IV: 100%.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min, reduce dose by 50% and monitor serum potassium. Use with caution in mild impairment.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
No specific adjustment; however, use with caution in severe hepatic impairment due to risk of hyperkalemia.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Not established; safety and efficacy in pediatric patients not determined.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Start at 5 m Eq orally daily; titrate slowly and monitor serum potassium due to age-related renal function decline.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
None
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Hyperkalemia risk, especially in patients with renal impairment,Cardiac effects: risk of arrhythmias with rapid correction or high doses,Gastrointestinal reactions: ulceration, bleeding, perforation with solid oral formulations,Use with caution in patients with renal insufficiency, adrenal insufficiency, diabetes, or cardiac disease,Monitor serum potassium levels and ECG during therapy
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia,Severe renal impairment with oliguria or anuria,Untreated Addison's disease,Solid oral potassium supplements in patients with delayed gastrointestinal transit
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes) in large amounts; limit salt substitutes containing potassium chloride. Take with food to minimize GI irritation.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregnant women as high potassium levels may pose risks. First trimester: No evidence of fetal harm. Second trimester: Monitor maternal potassium levels. Third trimester: Adjusted potassium requirements may occur due to increased renal clearance; maintain normokalemia.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium is excreted into breast milk in amounts not likely to cause adverse effects in nursing infants. The M/P ratio is approximately 0.4. Supplementation at physiological doses is considered compatible with breastfeeding. Monitor maternal serum potassium to avoid excessive dosage.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustment required for TEN-K based on pregnancy alone. However, pregnancy can increase renal clearance of potassium, potentially lowering serum levels. Monitor potassium levels and adjust dose if hypokalemia develops. Typical dose range: 20-100 m Eq/day, titrated according to serum potassium. Avoid excessive dosing to prevent hyperkalemia.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
TEN-K is a high-dose potassium chloride formulation (10 m Eq per tablet) used for hypokalemia. Do not split or crush tablets; they are extended-release to prevent GI irritation. Monitor serum potassium and renal function; avoid in severe renal impairment or hyperkalemia. Consider potential for esophageal ulceration if tablet lodges.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
Take with a full glass of water and with food or after a meal to reduce stomach upset.,Swallow tablets whole; do not crush, chew, or split them.,Avoid salt substitutes or potassium-containing supplements unless directed by your doctor.,Report signs of hyperkalemia: muscle weakness, irregular heartbeat, tingling in hands/feet.,Store at room temperature, away from moisture and heat.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEN-K vs KAON CL, answered by our medical review team.
TEN-K is a Electrolyte supplement that works by Potassium chloride is a potassium supplement that replaces potassium ions in the body, essential for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. It acts as a cofactor for numerous enzymes and is critical for myocardial and skeletal muscle contraction.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEN-K and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEN-K is: 10 m Eq (one tablet) orally once daily or as directed by physician.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEN-K and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEN-K is classified as Category C. No known teratogenic effects based on available data. Potassium supplementation does not increase risk of congenital anomalies above baseline. However, avoid hyperkalemia in pregna. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.